631 related articles for article (PubMed ID: 12425805)
1. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
2. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
3. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
6. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
7. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
8. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
Cheng ZQ; Yin W; Fan JY; Ma TJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
Rossini M; Gatti D; Zamberlan N; Braga V; Dorizzi R; Adami S
J Bone Miner Res; 1994 Nov; 9(11):1833-7. PubMed ID: 7863833
[TBL] [Abstract][Full Text] [Related]
12. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
13. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
15. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Ozdemir F; Rodoplu M
Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
17. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
Bettembuk P; Balogh A
Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
[TBL] [Abstract][Full Text] [Related]
18. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
[TBL] [Abstract][Full Text] [Related]
19. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]